Skip to main content
NCBI home page
British Journal of Pharmacology logoLink to British Journal of Pharmacology
. 1991 Dec;104(4):853–858. doi: 10.1111/j.1476-5381.1991.tb12517.x

Effects of Org 7797 on early, late and inducible arrhythmias following coronary artery occlusion in rats and dogs.

E Winslow 1, J K Campbell 1, E Barron 1, R J Marshall 1, A W Muir 1
PMCID: PMC1908862  PMID: 1810599

Abstract

1. The class Ic steroidal antiarrhythmic agent, Org 7797, was compared with two other Ic agents, flecainide and propafenone for intravenous activity against ischaemia-related cardiac arrhythmias and for electrophysiological actions in vivo. In addition the haemodynamic effects of Org 7797 were assessed in greyhounds. 2. Org 7797 (0.5 mg kg-1) significantly reduced the expected incidence of early ischaemia-induced ventricular fibrillation (VF) in rats and greyhound dogs and at doses of 0.5-1.0 mg kg-1 antagonized reperfusion-induced arrhythmias. Comparative studies in rats showed Org 7797 to be 2-4 times more potent than flecainide or propafenone. 3. Org 7797 (0.5 mg kg-1) slowed intracardiac conduction in anaesthetized beagles and again was at least 2-4 times more potent than flecainide or propafenone. 4. Org 7797 (0.5 and 2.0 mg kg-1), flecainide (1.0 and 2.0 mg kg-1) or propafenone (0.5 and 2.0 mg kg-1), did not significantly prevent induction of tachyarrhythmias (VT) in dogs with 5-6 day old myocardial infarcts although all 3 drugs appeared to prevent induced VF. All 3 drugs (notably flecainide) did however reduce the VT rate. 5. All 3 drugs (1-2 mg kg-1) suppressed spontaneous tachyarrhythmias in conscious beagle dogs with 1-2 day old infarcts. Propafenone was the least effective. 6. In an antifibrillatory dose (0.5 mg kg-1), the major haemodynamic effect of Org 7797 was a 10% increase in peripheral vascular resistance. Stroke volume, cardiac output and coronary blood flow were unchanged. In therapeutic doses, Org 7797 was also less negatively chronotropic than flecainide.(ABSTRACT TRUNCATED AT 250 WORDS)

Full text

PDF
853

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Burnett D. M., Gal J., Zahniser N. R., Nies A. S. Propafenone interacts stereoselectively with beta 1- and beta 2-adrenergic receptors. J Cardiovasc Pharmacol. 1988;12(5):615–619. doi: 10.1097/00005344-198811000-00017. [DOI] [PubMed] [Google Scholar]
  2. Campbell J. K., Logan R. T., Marshall R. J., McGarry G., Sleigh T., Winslow E. Antiarrhythmic activity of 17 beta-aminoestratrienes. Comparison of 3-ols and 3-acetates with the corresponding 3-(3-amino-2-hydroxypropyl) ethers. J Med Chem. 1986 Feb;29(2):244–250. doi: 10.1021/jm00152a013. [DOI] [PubMed] [Google Scholar]
  3. Clark C., Foreman M. I., Kane K. A., McDonald F. M., Parratt J. R. Coronary artery ligation in anesthetized rats as a method for the production of experimental dysrhythmias and for the determination of infarct size. J Pharmacol Methods. 1980 Jun;3(4):357–368. doi: 10.1016/0160-5402(80)90077-7. [DOI] [PubMed] [Google Scholar]
  4. Follmer C. H., Colatsky T. J. Block of delayed rectifier potassium current, IK, by flecainide and E-4031 in cat ventricular myocytes. Circulation. 1990 Jul;82(1):289–293. doi: 10.1161/01.cir.82.1.289. [DOI] [PubMed] [Google Scholar]
  5. Gang E. S., Bigger J. T., Jr, Uhl E. W. Effects of timolol and propranolol on inducible sustained ventricular tachyarrhythmias in dogs with subacute myocardial infarction. Am J Cardiol. 1984 Jan 15;53(2):275–281. doi: 10.1016/0002-9149(84)90439-9. [DOI] [PubMed] [Google Scholar]
  6. Harrison D. C. Antiarrhythmic drug classification: new science and practical applications. Am J Cardiol. 1985 Jul 1;56(1):185–187. doi: 10.1016/0002-9149(85)90591-0. [DOI] [PubMed] [Google Scholar]
  7. Janse M. J., Wilms-Schopman F., Opthof T. Mechanism of antifibrillatory action of Org 7797 in regionally ischemic pig heart. J Cardiovasc Pharmacol. 1990 Apr;15(4):633–643. doi: 10.1097/00005344-199004000-00017. [DOI] [PubMed] [Google Scholar]
  8. Janse M. J., Wit A. L. Electrophysiological mechanisms of ventricular arrhythmias resulting from myocardial ischemia and infarction. Physiol Rev. 1989 Oct;69(4):1049–1169. doi: 10.1152/physrev.1989.69.4.1049. [DOI] [PubMed] [Google Scholar]
  9. Kirchhof C., Wijffels M., Brugada J., Planellas J., Allessie M. Mode of action of a new class IC drug (ORG 7797) against atrial fibrillation in conscious dogs. J Cardiovasc Pharmacol. 1991 Jan;17(1):116–124. doi: 10.1097/00005344-199101000-00017. [DOI] [PubMed] [Google Scholar]
  10. Lazzara R., el-Sherif N., Scherlag B. J. Early and late effects of coronary artery occlusion on canine Purkinje fibers. Circ Res. 1974 Sep;35(3):391–399. doi: 10.1161/01.res.35.3.391. [DOI] [PubMed] [Google Scholar]
  11. Lederman S. N., Wenger T. L., Bolster D. E., Strauss H. C. Effects of flecainide on occlusion and reperfusion arrhythmias in dogs. J Cardiovasc Pharmacol. 1989 Apr;13(4):541–546. [PubMed] [Google Scholar]
  12. Marshall R. J., Muir A. W. The beneficial actions of bepridil in acute myocardial infarction in anaesthetized dogs. Br J Pharmacol. 1981 Jun;73(2):471–479. doi: 10.1111/j.1476-5381.1981.tb10445.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Nestico P. F., Morganroth J., Horowitz L. N. New antiarrhythmic drugs. Drugs. 1988 Mar;35(3):286–319. doi: 10.2165/00003495-198835030-00005. [DOI] [PubMed] [Google Scholar]
  14. Scherlag B. J., Helfant R. H., Haft J. I., Damato A. N. Electrophysiology underlying ventricular arrhythmias due to coronary ligation. Am J Physiol. 1970 Dec;219(6):1665–1671. doi: 10.1152/ajplegacy.1970.219.6.1665. [DOI] [PubMed] [Google Scholar]
  15. Uprichard A. C., Harron D. W. Atenolol, but not mexiletine, protects against stimulus-induced ventricular tachycardia in a chronic canine model. Br J Pharmacol. 1989 Jan;96(1):220–226. doi: 10.1111/j.1476-5381.1989.tb11803.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Walker M. J., Curtis M. J., Hearse D. J., Campbell R. W., Janse M. J., Yellon D. M., Cobbe S. M., Coker S. J., Harness J. B., Harron D. W. The Lambeth Conventions: guidelines for the study of arrhythmias in ischaemia infarction, and reperfusion. Cardiovasc Res. 1988 Jul;22(7):447–455. doi: 10.1093/cvr/22.7.447. [DOI] [PubMed] [Google Scholar]
  17. Wellens H. J., Brugada P., Farre J. Ventricular arrhythmias: mechanisms and actions of antiarrhythmic drugs. Am Heart J. 1984 May;107(5 Pt 2):1053–1057. doi: 10.1016/0002-8703(84)90174-1. [DOI] [PubMed] [Google Scholar]
  18. Winslow E., Campbell J. K., Barron E. Effects of amiodarone on cardiac electrophysiology and inducibility of arrhythmias in chronically infarcted dogs: late arrhythmias, haemodynamics, and sympatholytic actions. J Cardiovasc Pharmacol. 1990 Dec;16(6):896–904. doi: 10.1097/00005344-199012000-00006. [DOI] [PubMed] [Google Scholar]
  19. Winslow E., Martorana M., Bell P. Electrophysiologic effects of Org 7797, a new steroidal antiarrhythmic agent: comparison with class 1a, 1b, and 1c drugs. J Cardiovasc Pharmacol. 1989 Aug;14(2):205–212. doi: 10.1097/00005344-198908000-00004. [DOI] [PubMed] [Google Scholar]
  20. Zipes D. P., Troup P. J. New antiarrhythmic agents: amiodarone, aprindine, disopyramide, ethmozin, mexiletine, tocainide, verapamil. Am J Cardiol. 1978 May 22;41(6):1005–1024. doi: 10.1016/0002-9149(78)90853-6. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Pharmacology are provided here courtesy of The British Pharmacological Society

RESOURCES